Tilray Brands (TLRY) Aktienübersicht
Tilray Brands, Inc. ist ein Unternehmen für Lifestyle-Konsumgüter und beschäftigt sich mit der Erforschung, dem Anbau, der Verarbeitung und dem Vertrieb von medizinischen Cannabisprodukten in Kanada, den Vereinigten Staaten, Europa, dem Nahen Osten, Afrika und auf internationaler Ebene. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
TLRY Community Fair Values
Create NarrativeSee what 171 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tilray Brands, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$4.42 |
| 52-Wochen-Hoch | US$23.20 |
| 52-Wochen-Tief | US$3.67 |
| Beta | 1.92 |
| 1 Monat Veränderung | 0% |
| 3 Monate Veränderung | -18.30% |
| 1 Jahr Veränderung | -51.96% |
| 3 Jahre Veränderung | -83.13% |
| 5 Jahre Veränderung | -96.63% |
| Veränderung seit IPO | -97.25% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 29
TLRY: Beverage And Medical Expansion Will Drive Long Term Cash Flow
Analysts have reduced their fair value estimate for Tilray Brands, cutting the price target by about $3 after revising assumptions for revenue growth, profit margins and future P/E in light of more cautious expectations for international cannabis permits and beverage sales. What's in the News for Tilray Brands Tilray Medical launched its first medical cannabis product in Panama, Tilray Oral Solution CBD100, manufactured at its EU-GMP certified facility in Portugal and distributed through Farmacias Arrocha under medical prescription.Seeking Alpha • Jul 29
Tilray Q4: Dilution Outweighs Progress
Summary Tilray Brands delivered strong Q4 revenue growth, driven by the BrewDog acquisition, but shares hit new lows due to ongoing dilution. Despite revenue gains, most segment gross margins stagnated, and adjusted net income fell 60% year over year, highlighting persistent profitability challenges. The company's valuation remains quite depressed compared to peer Canopy Growth, which is expected to show more revenue growth. Read the full article on Seeking Alpha
Narrative-Update • Jul 14
TLRY: Partial Rescheduling And Medical Assets Will Support Future Cash Flow Visibility
Analysts have trimmed their 12 month price target for Tilray Brands to $5.00 from $6.50, citing updated expectations for slower revenue growth, slightly lower profit margins, and a reduced future P/E multiple following recent adjustments to sales forecasts and cannabis permit timing. Analyst Commentary Recent research updates on Tilray Brands highlight a more cautious tone, with several bearish analysts revisiting their revenue assumptions, margin outlook, and valuation frameworks in light of revised sales expectations and cannabis permit timing.Recent updates
Narrative-Update • Jul 29
TLRY: Beverage And Medical Expansion Will Drive Long Term Cash Flow
Analysts have reduced their fair value estimate for Tilray Brands, cutting the price target by about $3 after revising assumptions for revenue growth, profit margins and future P/E in light of more cautious expectations for international cannabis permits and beverage sales. What's in the News for Tilray Brands Tilray Medical launched its first medical cannabis product in Panama, Tilray Oral Solution CBD100, manufactured at its EU-GMP certified facility in Portugal and distributed through Farmacias Arrocha under medical prescription.Seeking Alpha • Jul 29
Tilray Q4: Dilution Outweighs Progress
Summary Tilray Brands delivered strong Q4 revenue growth, driven by the BrewDog acquisition, but shares hit new lows due to ongoing dilution. Despite revenue gains, most segment gross margins stagnated, and adjusted net income fell 60% year over year, highlighting persistent profitability challenges. The company's valuation remains quite depressed compared to peer Canopy Growth, which is expected to show more revenue growth. Read the full article on Seeking AlphaNarrative-Update • Jul 14
TLRY: Partial Rescheduling And Medical Assets Will Support Future Cash Flow Visibility
Analysts have trimmed their 12 month price target for Tilray Brands to $5.00 from $6.50, citing updated expectations for slower revenue growth, slightly lower profit margins, and a reduced future P/E multiple following recent adjustments to sales forecasts and cannabis permit timing. Analyst Commentary Recent research updates on Tilray Brands highlight a more cautious tone, with several bearish analysts revisiting their revenue assumptions, margin outlook, and valuation frameworks in light of revised sales expectations and cannabis permit timing.Narrative-Update • Jun 24
TLRY: Partial Cannabis Rescheduling And Beverage Partnerships Will Improve Future Cash Flow Visibility
Analysts recently trimmed their average 12 month price target for Tilray Brands to about $6.50 from roughly $9.00. This reflects updated assumptions for slower revenue growth, slightly lower profit margins, a higher discount rate and a reduced future P/E multiple, even as some research cites potential benefits from partial cannabis re scheduling.
Narrative-Update • Jun 06
TLRY: Cannabis Rescheduling And Margin Outlook Will Drive Future Upside Potential
Tilray Brands' consensus analyst price target has been reset lower by roughly $2 to $3 per share as analysts factor in updated cannabis re-scheduling expectations and revised profit margin and future P/E assumptions following recent firm-level target cuts and one upgrade. Analyst Commentary Recent Street research on Tilray Brands shows a mix of optimism around potential regulatory shifts and caution around profit expectations and valuation multiples.Narrative-Update • May 17
TLRY: BrewDog Deal And Cannabis Rescheduling Will Shape Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands by a few dollars to reflect updated assumptions around discount rates, profit margins and future P/E multiples, even as some highlight potential benefits from partial cannabis rescheduling and recent acquisitions. Analyst Commentary Bullish Takeaways Bullish analysts view the partial cannabis rescheduling order as extremely favorable, seeing scope for improved sector sentiment and potential support for valuation multiples if regulatory risk is perceived as lower.Narrative-Update • May 02
TLRY: BrewDog Acquisition And Cannabis Rescheduling Will Drive Future Upside
Analysts have cut their average price target on Tilray Brands to about $10.04 from $16.17, reflecting updated assumptions on discount rates, revenue growth, profit margins, and a reset future P/E following recent research that includes target reductions tied to the BrewDog asset acquisition and evolving views on potential U.S. cannabis rescheduling. Analyst Commentary Recent research on Tilray Brands highlights a mix of optimism around regulatory developments and caution around execution risks, especially following the BrewDog asset acquisition and a series of price target resets.Narrative-Update • Apr 18
TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential
The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.Narrative-Update • Apr 04
TLRY: BrewDog Acquisition Execution Will Support Long Term Cash Flow Visibility
Tilray Brands' updated analyst price target framework now points to an implied fair value shift from $19.22 to $20.25. Analysts cite changes to revenue growth assumptions, profit margin expectations, and a higher future P/E multiple following a mix of price target cuts and a recent upgrade on the stock.Narrative-Update • Mar 20
TLRY: BrewDog Acquisition Synergies And Schedule III Shift Will Improve Cash Flow Visibility
Analysts have reduced their Tilray Brands price targets to $9.00 from $10.00, reflecting caution regarding the BrewDog asset acquisition and a focus on the company demonstrating it can achieve operational synergies, as well as provide clearer long term visibility into sales and cash flows. Analyst Commentary Recent research updates point to a cautious stance on Tilray Brands, with several Bearish analysts trimming price targets and reiterating more neutral views after both the BrewDog asset acquisition and the latest quarterly results.Narrative-Update • Mar 05
TLRY: Schedule III Shift And Medical Push Will Improve Cash Flow Visibility
Narrative Update on Tilray Brands The analyst price target for Tilray Brands has been trimmed from $9.25 to $9.00 as analysts factor in a slightly higher discount rate, a lower assumed future P/E, and execution risks and synergy uncertainty around the BrewDog asset acquisition, even though revenue growth and profit margin assumptions remain modestly higher. Analyst Commentary Recent Street research on Tilray Brands has leaned cautious, with multiple bearish analysts trimming price targets and maintaining neutral stances despite some operational positives.Narrative-Update • Feb 19
TLRY: Rescheduling And Licensing Agreements Will Support Long Term Cash Flow Visibility
Analysts have updated their price target on Tilray Brands to $19.22 from $1.83, reflecting revised assumptions around revenue growth, profit margins, and future P/E following recent coverage initiations and target resets that cited solid Q2 sales with mixed visibility on long-term sales and cash flow. Analyst Commentary Recent Street commentary around Tilray Brands has been mixed, with some firms trimming price targets while keeping ratings neutral.Narrative-Update • Feb 05
TLRY: Schedule III Rescheduling And Medical Expansion Will Support Cash Flow Visibility
Analysts have trimmed their price targets on Tilray Brands to around $10, reflecting a more cautious stance after recent quarterly results that they viewed as generally in line. Solid international and distribution sales were partly offset by ongoing questions around long term sales visibility and cash flow.Narrative-Update • Jan 21
TLRY: Schedule III Shift Will Test Medical Expansion And Cash Flow Visibility
Analysts have adjusted their fair value estimate for Tilray Brands from $8.50 to $9.25, citing recent target revisions that reflect more cautious revenue growth assumptions, steady profitability expectations, and an updated outlook for the future price-to-earnings ratio. Analyst Commentary Recent Street research has leaned cautious on Tilray Brands, with bearish analysts trimming price targets and flagging risks around visibility into the company’s longer term financial profile.Analyseartikel • Jan 16
Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop
To the annoyance of some shareholders, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares are down a considerable 30% in the...Narrative-Update • Jan 06
TLRY: Rescheduling To Schedule III Will Expose Medical Expansion Hurdles
Analysts have lifted their fair value estimate for Tilray Brands to $8.50 from $0.60, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they see as better reflecting the company’s current risk and earnings profile. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act.Narrative-Update • Dec 20
TLRY: Reverse Split Will Drive Future Upside As Medical Expansion Advances
Analysts have modestly raised their price target on Tilray Brands to reflect slightly stronger long term revenue growth expectations, even as they factor in significantly compressed profit margins and a sharply higher assumed future price to earnings multiple. What's in the News Tilray Medical outlined a strategic framework for U.S. medical cannabis expansion following federal rescheduling, creating Tilray Medical USA Inc.Narrative-Update • Dec 06
TLRY: Reverse Split And Medical Expansion Will Drive Future Upside
Analysts have significantly raised their price target on Tilray Brands, lifting fair value expectations from approximately $1.78 to $16.17 per share, citing improved long term earnings visibility and a more favorable valuation multiple outlook. What's in the News Announced a 1 for 10 reverse stock split effective December 2, 2025, aiming to support continued Nasdaq listing and broaden institutional investor eligibility (company announcement).Analyseartikel • Nov 24
Tilray Brands, Inc. (NASDAQ:TLRY) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
The Tilray Brands, Inc. ( NASDAQ:TLRY ) share price has fared very poorly over the last month, falling by a substantial...Narrative-Update • Nov 22
TLRY: Federal Policy Shifts Will Drive New U.S. Cannabis Opportunities
Analysts have raised Tilray Brands' price target from $1.50 to $2.00, citing strengthened expectations due to shifting U.S. federal policy toward cannabis and the company's strong market position. Analyst Commentary Analysts have highlighted a range of factors that support an optimistic outlook for Tilray Brands, while also noting certain risks that could affect the company's future performance.Narrative-Update • Nov 07
TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access
Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.Narrative-Update • Oct 23
Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets
Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.Narrative-Update • Oct 09
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Analysts have raised their price target for Tilray Brands from $1.50 to $2.00, citing anticipated progress in U.S. cannabis policy and Tilray's strong positioning to benefit from broader market access. Analyst Commentary Recent commentary from bullish analysts highlights both the strengths and potential hurdles facing Tilray Brands in the evolving cannabis market.Analyseartikel • Oct 03
Tilray Brands, Inc.'s (NASDAQ:TLRY) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have continued their recent momentum with a 29% gain in the last month...Narrative-Update • Aug 26
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Tilray Brands’ consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray’s strong positioning to benefit from expanding market opportunities. Analyst Commentary Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.Analyseartikel • Aug 18
Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have been powering on, with a gain of 66% in...Analyseartikel • Jul 04
Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth
Tilray Brands, Inc. ( NASDAQ:TLRY ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Aktionärsrenditen
| TLRY | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -4.7% | 3.2% | 2.7% |
| 1Y | -52.0% | 57.6% | 20.9% |
Rendite im Vergleich zur Industrie: TLRY unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 57.6% erzielte.
Rendite vs. Markt: TLRY hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.9 erzielte.
Preisvolatilität
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: TLRY hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: TLRYDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 16% auf 6% zurückgegangen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| n/a | 3,595 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc., ein Anbieter von Lifestyle-Konsumgütern, ist in den Bereichen Forschung, Anbau, Verarbeitung und Vertrieb von medizinischen Cannabisprodukten in Kanada, den Vereinigten Staaten, Europa, dem Nahen Osten, Afrika und weltweit tätig. Das Unternehmen ist in vier Geschäftsbereichen tätig: Getränke, Cannabis, Vertrieb und Wellness. Es bietet zudem medizinische Cannabisprodukte sowie Cannabisprodukte für Erwachsene an, vertreibt und verkauft pharmazeutische Produkte und Wellness-Produkte und produziert, vermarktet und verkauft Getränke sowie Lebensmittel auf Hanfbasis.
Tilray Brands, Inc.'s Grundlagenzusammenfassung
| TLRY grundlegende Statistiken | |
|---|---|
| Marktanteil | US$619.76m |
| Gewinn(TTM) | -US$121.40m |
| Umsatz(TTM) | US$915.45m |
0.7x
Kurs-Umsatz-Verhältnis-4.9x
Kurs-Gewinn-Verhältnis Ist TLRY zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| TLRY Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$915.45m |
| Kosten der Einnahmen | US$652.86m |
| Bruttogewinn | US$262.59m |
| Sonstige Ausgaben | US$383.99m |
| Gewinn | -US$121.40m |
Zuletzt gemeldete Gewinne
May 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.90 |
| Bruttomarge | 28.68% |
| Nettogewinnspanne | -13.26% |
| Schulden/Eigenkapital-Verhältnis | 14.2% |
Wie hat sich TLRY auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/10 22:51 |
| Aktienkurs zum Tagesende | 2026/08/10 00:00 |
| Gewinne | 2026/05/31 |
| Jährliche Einnahmen | 2026/05/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Tilray Brands, Inc. wird von 27 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |